Sanjay Phogat

Sanofi Pasteur, USA

Title: HIV vaccine development: An industrial perspective


"Sanjay Phogat, currently holds the position of Director, New Vaccine Project Leader for Sanofi Pasteur and is based in Swiftwater, Pennsylvania. Prior to joining Sanofi Pasteur in 2011, Sanjay held positions such as Associate Director, Principal Scientist, Project Manager, Neutralizing antibody consortium Principal Investigator at International AIDS Vaccine Initiative (IAVI) in Brooklyn, New York. At IAVI, he lead the efforts and was a key member of the discovery team that isolated and characterized novel, potent broadly neutralizing antibodies (bNAbs), which are considered a “milestone achievement” in the field of HIV vaccine research. He has a wealth of experience in HIV-1 neutralizing antibodies and envelope based vaccine candidates. He also worked as a Research Assistant Professor at the State University of New York, Downstate Medical Center, Brooklyn, New York, Research fellow at the Vaccine Research Center, NIAID, NIH and Post-doctoral Fellow at NCI-Frederick and USUHS, in Bethesda, Maryland. He holds a Ph.D. in Genetics from the from the University of Delhi, Delhi, India, an M.S. in Biotechnology from Madurai Kamaraj University in Chennai, India, and a B.S. in Microbiology from University of Delhi in India. He has numerous publications in peer reviewed journals and participates as associate editor/reviewer for certain peer-reviewed journals."


"Even after two decade of HIV vaccine R&D, challenges posed by HIV vaccine development require us to rethink the traditional R&D industry vaccine development model and necessitate the establishment of broad-based public-private partnerships. The complexities of an HIV vaccine present many unknowns, both with respect to scientific, pre-clinical, clinical development and industrialization. Sanofi Pasteur has been working on the development of an effective HIV vaccine for over two decades. It is now clear that the roadmap to developing an effective HIV vaccine is best managed by broad-based partnerships, not individual entities. A unique collaboration has emerged following the successful RV144 results, with the objective of pursuing research and development of the pox-prime/protein-boost HIV vaccine regimen. The Pox-Protein Public-Private Partnership (P5) is an informal partnership between the U.S. National Institute for Allergies and Infectious Diseases (NIAID of the U.S. National Institute of health), The Bill & Melinda Gates Foundation (BMGF), the HIV Vaccine Trials Network (HVTN), the U.S. Military HIV Research Program (MHRP), Sanofi Pasteur, and Novartis vaccines. This collaboration is expected to further the field of HIV vaccine development by sharing resources and joining the forces of vaccine manufacturing, funding agencies, research organizations, governments, and experts in the field of HIV vaccine development. HIV vaccine development is a global responsibility. To ensure an effective HIV vaccine will be delivered as quickly as possible, industry, academia, public sector, NGO and donors must work simultaneously in partnerships The presentation will highlight two topics. An industrial perspectiv"

Speaker Presentations

Speaker PDFs